Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cytek Biosciences Inc (CTKB)

Cytek Biosciences Inc (CTKB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 736,442
  • Shares Outstanding, K 131,273
  • Annual Sales, $ 193,020 K
  • Annual Income, $ -12,150 K
  • 60-Month Beta 1.33
  • Price/Sales 3.80
  • Price/Cash Flow 221.22
  • Price/Book 1.87
Trade CTKB with:

Options Overview Details

View History
  • Implied Volatility 199.95% ( +90.66%)
  • Historical Volatility 45.12%
  • IV Percentile 95%
  • IV Rank 74.34%
  • IV High 268.34% on 04/22/24
  • IV Low 1.84% on 10/12/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 9
  • Volume Avg (30-Day) 12
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 200
  • Open Int (30-Day) 146

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.03
  • Number of Estimates 5
  • High Estimate -0.02
  • Low Estimate -0.04
  • Prior Year -0.02
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.26 +6.44%
on 06/27/24
6.52 -14.11%
on 06/12/24
-0.03 (-0.53%)
since 05/31/24
3-Month
5.26 +6.44%
on 06/27/24
7.02 -20.23%
on 04/09/24
-0.92 (-14.11%)
since 04/02/24
52-Week
3.80 +47.37%
on 11/08/23
9.87 -43.26%
on 12/26/23
-2.94 (-34.43%)
since 06/30/23

Most Recent Stories

More News
Why Shares of Cytek Biosciences Dropped This Week

Cytek grew revenue and losses in the first quarter.

CTKB : 5.60 (-0.18%)
Cytek Biosciences Set to Join S&P SmallCap 600

/PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening...

SPGI : 450.45 (+0.93%)
CTKB : 5.60 (-0.18%)
CSII : 20.00 (+0.15%)
ABT : 103.20 (unch)
Cytek Biosciences Reports Second Quarter 2022 Financial Results

Second quarter revenue grew 32% compared to prior year...

CTKB : 5.60 (-0.18%)
Cytek to Participate in the 42nd Annual Canaccord Genuity Global Growth Conference

FREMONT, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced the company...

CTKB : 5.60 (-0.18%)
Cytek Biosciences to Report Second Quarter 2022 Financial Results on August 10, 2022

FREMONT, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will...

CTKB : 5.60 (-0.18%)
Kunlun Capital Helps Medical Companies Grow in the Long Run

/PRNewswire/ -- Recently, Yahui Zhou, the founding partner of Kunlun Capital, won the 36kr 2022 " China 100 Best Investors Voted by Entrepreneurs " award and...

CTKB : 5.60 (-0.18%)
Cytek Biosciences to Host Inaugural Analyst and Investor Day

FREMONT, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) announced today that it will...

CTKB : 5.60 (-0.18%)
Cytek® Biosciences Receives CE Marking for Series of cFluor® Reagents, TBNK Kit

Company Moves to Make Total Cell Analysis Solutions Available for Clinical Applications in the European Market...

CTKB : 5.60 (-0.18%)
Cytek Biosciences Reports First Quarter 2022 Financial Results

First quarter revenue grew 44% compared to prior year...

CTKB : 5.60 (-0.18%)
Cytek BioSciences Enters Oversold Territory (CTKB)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

CTKB : 5.60 (-0.18%)

Business Summary

Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in FREMONT, Calif.

See More

Key Turning Points

3rd Resistance Point 5.91
2nd Resistance Point 5.83
1st Resistance Point 5.72
Last Price 5.60
1st Support Level 5.52
2nd Support Level 5.44
3rd Support Level 5.33

See More

52-Week High 9.87
Fibonacci 61.8% 7.55
Fibonacci 50% 6.84
Fibonacci 38.2% 6.12
Last Price 5.60
52-Week Low 3.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar